Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against norovirus infection. Findings show a 30% reduction in infection rates among vaccinated participants compared to those receiving a placebo, along with reduced viral shedding and increased levels of protective antibodies in blood and mucosal tissues.